Impact of early disease factors on metabolic syndrome in systemic lupus erythematosus: Data from an international inception cohort

Annals of the Rheumatic Diseases

Volumn 74, Issue 8, 2015, Pages 1530-1536

  Parker, Ben ^a,b   Urowitz, Murray B ^c   Gladman, Dafna D ^c   Lunt, Mark ^a,b   Donn, Rachelle ^a   Bae, Sang Cheol ^d   Sanchez Guerrero, Jorge ^e   Romero Diaz, Juanita ^e   Gordon, Caroline ^f   Wallace, Daniel J ^g   Clarke, Ann E ^h   Bernatsky, Sasha ^h   Ginzler, Ellen M ⁱ   Isenberg, David A ^j   Rahman, Anisur ^j   Merrill, Joan T ^k   Alarcón, Graciela S ^l   Fessler, Barri J ^l   Fortin, Paul R ^m   Hanly, John G ⁿ   Petri, Michelle ^o   Steinsson, Kristjan ^p   Dooley, Mary Anne ^q   Manzi, Susan ^r   Khamashta, Munther A ^s   Ramsey Goldman, Rosalind ^t   Zoma, Asad A ^u   Sturfelt, Gunnar K ^v   Nived, Ola ^v   Aranow, Cynthia ^w   Mackay, Meggan ^w   Ramos Casals, Manuel ^x   Van Vollenhoven, Ronald F ^y   Kalunian, Kenneth C ^z   Ruiz Irastorza, Guillermo ^aa   Lim, S Sam ^ab   Kamen, Diane L ^ac   Peschken, Christine A ^ad   Inanc, Murat ^ae   Bruce, Ian N ^a,b   more..

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

^b MANCHESTER UNIVERSITY NHS FOUNDATION TRUST   (United Kingdom)

^c UNIVERSITY OF TORONTO   (Canada)

^d Hanyang Institute of Bioscience and Biotechnology   (South Korea)

^e INSTITUTO NACIONAL DE CIENCIAS MÉDICAS Y NUTRICIÓN SALVADOR ZUBIRÁN   (Mexico)

^f UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^g UNIVERSITY OF CALIFORNIA   (United States)

^h MONTREAL GENERAL HOSPITAL   (Canada)

ⁱ Downstate Health Sciences University   (United States)

^j UNIVERSITY COLLEGE LONDON   (United Kingdom)

^k OKLAHOMA MEDICAL RESEARCH FOUNDATION   (United States)

^l University of Alabama at Birmingham   (United States)

^m LAVAL UNIVERSITY   (Canada)

ⁿ QUEEN ELIZABETH II HEALTH SCIENCES CENTRE   (Canada)

^o JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^p LANDSPITALI UNIVERSITY HOSPITAL   (Iceland)

^q UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^r ALLEGHENY HEALTH NETWORK   (United States)

^s ST THOMAS HOSPITAL   (United Kingdom)

^t NORTHWESTERN UNIVERSITY   (United States)

^u HAIRMYRES HOSPITAL   (United Kingdom)

^v LUND UNIVERSITY HOSPITAL   (Sweden)

^w FEINSTEIN INSTITUTE FOR MEDICAL RESEARCH   (United States)

^x HOSPITAL CLÍNIC   (Spain)

^y KAROLINSKA INSTITUTE   (Sweden)

^z UNIVERSITY OF CALIFORNIA   (United States)

^aa HOSPITAL DE CRUCES   (Spain)

^ab EMORY UNIVERSITY   (United States)

^ac MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^ad UNIVERSITY OF MANITOBA   (Canada)

^ae ISTANBUL UNIVERSITY   (Turkey)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID;

ADULT; AFRICAN; AFRICAN AMERICAN; AGE; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE ACTIVITY; EXPOSURE; FEMALE; FOLLOW UP; HISPANIC; HUMAN; KIDNEY DISEASE; KOREAN (PEOPLE); LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; MUSCULOSKELETAL DISEASE ASSESSMENT; PHENOTYPE; PREVALENCE; PRIORITY JOURNAL; SYSTEMIC LUPUS ERYTHEMATOSUS; SYSTEMIC LUPUS INTERNATIONAL COLLABORATING CLINICS DAMAGE INDEX; COMORBIDITY; LUPUS ERYTHEMATOSUS, SYSTEMIC; MIDDLE AGED; STATISTICAL MODEL; YOUNG ADULT;

ADULT; COHORT STUDIES; COMORBIDITY; FEMALE; HUMANS; LOGISTIC MODELS; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; METABOLIC SYNDROME X; MIDDLE AGED; PHENOTYPE; PREVALENCE; YOUNG ADULT;

EID: 84940393297     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/annrheumdis-2013-203933     Document Type: Article

References (29)

1. Manzi S, Meilahn EN, Rairie JE, et al. Age-specific incidence rates of myocardial infarction and angina in women with systemic lupus erythematosus: comparison with the Framingham Study. Am J Epidemiol 1997;145:408-15.
2. Petri MA, Kiani AN, Post W, et al. Lupus Atherosclerosis Prevention Study (LAPS). Ann Rheum Dis 2011;70:760-5.
3. Ahmad Y, Shelmerdine J, Bodill H, et al. Subclinical atherosclerosis in systemic lupus erythematosus (SLE): the relative contribution of classic risk factors and the lupus phenotype. Rheumatology 2007;46:983-8.
4. Roman MJ, Shanker BA, Davis A, et al. Prevalence and correlates of accelerated atherosclerosis in systemic lupus erythematosus. N Engl J Med 2003;349:2399-406.
5. El-Magadmi M, Bodill H, Ahmad Y, et al. Systemic lupus erythematosus: an independent risk factor for endothelial dysfunction in women. Circulation 2004;110:399-404.
6. Bruce IN, Urowitz MB, Gladman DD, et al. Risk factors for coronary heart disease in women with systemic lupus erythematosus: the Toronto Risk Factor Study. Arthritis Rheum 2003;48:3159-67.
7. Esdaile JM, Abrahamowicz M, Grodzicky T, et al. Traditional Framingham risk factors fail to fully account for accelerated atherosclerosis in systemic lupus erythematosus. Arthritis Rheum 2001;44:2331-7.
8. Alberti KG, Zimmet P, Shaw J. Metabolic syndrome-A new world-wide definition. A Consensus Statement from the International Diabetes Federation. Diabet Med 2006;23:469-80.
9. Cornier MA, Dabelea D, Hernandez TL, et al. The metabolic syndrome. Endocr Rev 2008;29:777-822.
10. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive Summary of the Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001;285:2486-97.
11. Parker B, Bruce IN. The metabolic syndrome in systemic lupus erythematosus. Rheum Dis Clin North Am 2010;36:81-97.
12. Parker B, Urowitz MB, Gladman DD, et al. Clinical associations of the metabolic syndrome in systemic lupus erythematosus: data from an international inception cohort. Ann Rheum Dis 2013;72:1308-14.
13. Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1997;40:1725.
14. Alberti KG, Eckel RH, Grundy SM, et al. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and international association for the Study of Obesity. Circulation 2009;120:1640-5.
15. Gladman DD, Ibanez D, Urowitz MB. Systemic lupus erythematosus disease activity index 2000. J Rheumatol 2002;29:288-91.
16. Gladman D, Ginzler E, Goldsmith C, et al. The development and initial validation of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology damage index for systemic lupus erythematosus. Arthritis Rheum 1996;39:363-9.
17. Rojas RA, guilar-Salinas CA, Jimenez-Corona A, et al. Metabolic syndrome in Mexican adults: results from the National Health and Nutrition Survey 2006. Salud Publica Mex 2010;52(Suppl 1):S11-18.
18. Lorenzo C, Williams K, Hunt KJ, et al. The National Cholesterol Education Program-Adult Treatment Panel III, International Diabetes Federation, and World Health Organization definitions of the metabolic syndrome as predictors of incident cardiovascular disease and diabetes. Diabetes Care 2007;30:8-13.
19. Parker B, Ahmad Y, Shelmerdine J, et al. An analysis of the metabolic syndrome phenotype in systemic lupus erythematosus. Lupus 2011;20:1459-65.
20. Bellomio V, Spindler A, Lucero E, et al. Metabolic syndrome in Argentinean patients with systemic lupus erythematosus. Lupus 2009;18:1019-25.
21. Sabio JM, Zamora-Pasadas M, Jimenez-Jaimez J, et al. Metabolic syndrome in patients with systemic lupus erythematosus from Southern Spain. Lupus 2008;17:849-59.
22. Negron AM, Molina MJ, Mayor AM, et al. Factors associated with metabolic syndrome in patients with systemic lupus erythematosus from Puerto Rico. Lupus 2008;17:348-54.
23. Chung CP, Avalos I, Oeser A, et al. High prevalence of the metabolic syndrome in patients with systemic lupus erythematosus: association with disease characteristics and cardiovascular risk factors. Ann Rheum Dis 2007;66:208-14.
24. Telles R, Lanna C, Ferreira G, et al. Metabolic syndrome in patients with systemic lupus erythematosus: association with traditional risk factors for coronary heart disease and lupus characteristics. Lupus 2010;19:803-9.
25. Sabio JM, Vargas-Hitos J, Zamora-Pasadas M, et al. Metabolic syndrome is associated with increased arterial stiffness and biomarkers of subclinical atherosclerosis in patients with systemic lupus erythematosus. J Rheumatol 2009;36:2204-11.
26. Ryan MJ, McLemore GR Jr., Hendrix ST. Insulin resistance and obesity in a mouse model of systemic lupus erythematosus. Hypertension 2006;48:988-93.
27. Condon MB, Ashby D, Pepper RJ, et al. Prospective observational single-centre cohort study to evaluate the effectiveness of treating lupus nephritis with rituximab and mycophenolate mofetil but no oral steroids. Ann Rheum Dis 2013;72:1280-6.
28. Wallace DJ, Metzger AL, Stecher VJ, et al. Cholesterol-lowering effect of hydroxychloroquine in patients with rheumatic disease: reversal of deleterious effects of steroids on lipids. Am J Med 1990;89:322-6.
29. Penn SK, Kao AH, Schott LL, et al. Hydroxychloroquine and glycemia in women with rheumatoid arthritis and systemic lupus erythematosus. J Rheumatol 2010;37:1136-42.